Cordis Receives FDA Clearance for Vascular Stent Systems for Use in SFA
Cordis Corp. has announced it has received FDA clearance for its S.M.A.R.T. CONTROL vascular stent systems for use in the superficial femoral artery and/or the proximal popliteal artery, according to a news release.
Cordis, part of the Johnson & Johnson family of companies, said the S.M.A.R.T. stent is the first stent in the Unites States with both iliac and SFA indications.
"We are very pleased to offer an expanded indication for the S.M.A.R.T. stent," said Shlomi Nachman, worldwide president of Cordis, in the release. "Our goal is to continue to make expanded indications and new products available to our customers so they may bring these innovations to their patients."
Related Articles on FDA Clearances:
© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
New from Becker's ASC Review
Need a new supply management strategy? 5 key stepsRead Now
- Qui tam suits on the rise emphasizes need for ASC compliance plans
- To prevent patient leakage, turn to technology
- Real estate considerations for ASCs
- The Amazon.com for ASCs: Using collaborative consumption to improve the bottom line
- Lolo Jones shares lessons for overcoming failure at Becker's ASC Annual Meeting